Geode Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $791M | Sell |
2,635,840
-24,545
| -0.9% | -$7.4M | 0.04% | 347 |
|
|
2026
Q1 | $885M | Buy |
2,660,385
+9,663
| +0.4% | +$3.29M | 0.06% | 295 |
|
|
2025
Q4 | $1.06B | Buy |
2,650,722
+151,480
| +6% | +$67M | 0.07% | 246 |
|
|
2025
Q3 | $1.14B | Buy |
2,499,242
+100,472
| +4% | +$40.9M | 0.07% | 234 |
|
|
2025
Q2 | $780M | Buy |
2,398,770
+75,936
| +3% | +$21M | 0.05% | 304 |
|
|
2025
Q1 | $626M | Buy |
2,322,834
+116,034
| +5% | +$29.8M | 0.05% | 335 |
|
|
2024
Q4 | $518M | Buy |
2,206,800
+59,597
| +3% | +$15.7M | 0.04% | 382 |
|
|
2024
Q3 | $589M | Buy |
2,147,203
+66,928
| +3% | +$17.4M | 0.05% | 341 |
|
|
2024
Q2 | $505M | Buy |
2,080,275
+78,557
| +4% | +$12.4M | 0.04% | 350 |
|
|
2024
Q1 | $299M | Buy |
2,001,718
+74,982
| +4% | +$12.5M | 0.03% | 487 |
|
|
2023
Q4 | $368M | Buy |
1,926,736
+87,231
| +5% | +$14.9M | 0.04% | 409 |
|
|
2023
Q3 | $325M | Buy |
1,839,505
+37,483
| +2% | +$7.15M | 0.04% | 412 |
|
|
2023
Q2 | $342M | Buy |
1,802,022
+63,907
| +4% | +$12.7M | 0.04% | 400 |
|
|
2023
Q1 | $348M | Buy |
1,738,115
+48,186
| +3% | +$10.1M | 0.05% | 383 |
|
|
2022
Q4 | $401M | Buy |
1,689,929
+90,455
| +6% | +$19.3M | 0.06% | 335 |
|
|
2022
Q3 | $320M | Buy |
1,599,474
+26,771
| +2% | +$5.11M | 0.05% | 364 |
|
|
2022
Q2 | $229M | Buy |
1,572,703
+2,420
| +0.2% | +$343K | 0.03% | 461 |
|
|
2022
Q1 | $256M | Buy |
1,570,283
+64,992
| +4% | +$9.9M | 0.03% | 482 |
|
|
2021
Q4 | $255M | Buy |
1,505,291
+51,272
| +4% | +$9.53M | 0.03% | 488 |
|
|
2021
Q3 | $274M | Buy |
1,454,019
+8,001
| +0.6% | +$1.5M | 0.04% | 448 |
|
|
2021
Q2 | $245M | Buy |
1,446,018
+59,719
| +4% | +$8.75M | 0.03% | 470 |
|
|
2021
Q1 | $195M | Buy |
1,386,299
+77,166
| +6% | +$11.6M | 0.03% | 506 |
|
|
2020
Q4 | $170M | Buy |
1,309,133
+49,330
| +4% | +$6.59M | 0.03% | 511 |
|
|
2020
Q3 | $183M | Sell |
1,259,803
-24,493
| -2% | -$3.48M | 0.04% | 430 |
|
|
2020
Q2 | $190M | Sell |
1,284,296
-69,632
| -5% | -$9.39M | 0.04% | 390 |
|
|
2020
Q1 | $147M | Buy |
1,353,928
+114,441
| +9% | +$13.2M | 0.04% | 398 |
|
|
2019
Q4 | $143M | Buy |
1,239,487
+50,788
| +4% | +$5.06M | 0.03% | 496 |
|
|
2019
Q3 | $95.5M | Buy |
1,188,699
+128,504
| +12% | +$10.2M | 0.02% | 587 |
|
|
2019
Q2 | $76.9M | Buy |
1,060,195
+53,973
| +5% | +$4.14M | 0.02% | 673 |
|
|
2019
Q1 | $94M | Buy |
1,006,222
+90,689
| +10% | +$7.58M | 0.02% | 561 |
|
|
2018
Q4 | $66.7M | Buy |
915,533
+34,770
| +4% | +$2.67M | 0.02% | 619 |
|
|
2018
Q3 | $77M | Buy |
880,763
+74,018
| +9% | +$7.45M | 0.02% | 602 |
|
|
2018
Q2 | $79.4M | Buy |
806,745
+41,401
| +5% | +$4.11M | 0.02% | 576 |
|
|
2018
Q1 | $91.1M | Buy |
765,344
+17,698
| +2% | +$2.28M | 0.03% | 523 |
|
|
2017
Q4 | $94.9M | Buy |
747,646
+88,119
| +13% | +$11.1M | 0.03% | 503 |
|
|
2017
Q3 | $77.5M | Sell |
659,527
-2,878
| -0.4% | -$246K | 0.03% | 533 |
|
|
2017
Q2 | $52.8M | Buy |
662,405
+85,608
| +15% | +$5.47M | 0.02% | 632 |
|
|
2017
Q1 | $29.6M | Buy |
576,797
+42,781
| +8% | +$1.98M | 0.01% | 896 |
|
|
2016
Q4 | $20M | Buy |
534,016
+14,111
| +3% | +$591K | 0.01% | 1081 |
|
|
2016
Q3 | $35.2M | Buy |
519,905
+20,289
| +4% | +$1.43M | 0.02% | 699 |
|
|
2016
Q2 | $27.7M | Buy |
499,616
+19,435
| +4% | +$1.22M | 0.02% | 761 |
|
|
2016
Q1 | $30.1K | Buy |
480,181
+31,627
| +7% | +$2.1M | 0.02% | 711 |
|
|
2015
Q4 | $42.2M | Buy |
448,554
+10,371
| +2% | +$962K | 0.02% | 571 |
|
|
2015
Q3 | $35.2M | Buy |
438,183
+3,827
| +0.9% | +$425K | 0.02% | 625 |
|
|
2015
Q2 | $52M | Buy |
434,356
+23,380
| +6% | +$2.79M | 0.03% | 517 |
|
|
2015
Q1 | $42.9M | Buy |
410,976
+63,014
| +18% | +$6.39M | 0.02% | 566 |
|
|
2014
Q4 | $33.8M | Buy |
347,962
+18,137
| +5% | +$1.68M | 0.02% | 627 |
|
|
2014
Q3 | $25.8M | Buy |
329,825
+5,617
| +2% | +$362K | 0.02% | 709 |
|
|
2014
Q2 | $20.5M | Buy |
324,208
+10,614
| +3% | +$631K | 0.01% | 833 |
|
|
2014
Q1 | $21.1M | Buy |
313,594
+28,989
| +10% | +$2.24M | 0.01% | 789 |
|
|
2013
Q4 | $18.3M | Buy |
284,605
+32,238
| +13% | +$1.92M | 0.01% | 831 |
|
|
2013
Q3 | $16.2M | Buy |
252,367
+32,709
| +15% | +$1.63M | 0.01% | 791 |
|
|
2013
Q2 | $6.81M | Buy |
+219,658
| New | +$5.84M | 0.01% | 1210 |
|
Other funds holding ALNY
VPM
VCM
Geode Capital Management's ALNY Position: Q2 2026 in Review
Geode Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.92% in Q2 2026, selling an estimated $7.4M and leaving 2,635,840 shares worth $791M. The position accounts for 0.04% of the portfolio, ranked #347.
Geode Capital Management first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.14B in Q3 2025. 594 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Geode Capital Management held 2,635,840 shares of Alnylam Pharmaceuticals worth $791M as of Q2 2026.
- Geode Capital Management sold 24,545 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.4M.
- Alnylam Pharmaceuticals made up 0.04% of Geode Capital Management's portfolio in Q2 2026, its #347 holding.
- Geode Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Geode Capital Management's Alnylam Pharmaceuticals position peaked at $1.14B in Q3 2025.
- 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.